**Aditxt Discloses Information About Compliance with Nasdaq Listing Requirements in 8-K Filing** **

**

Aditxt, Inc. recently shared key updates via a virtual stakeholder update and Q&A session led by its Chief Executive Officer, Amro Albanna. The session, held on November 1, 2024, aimed to address concerns related to the company’s compliance with Nasdaq’s minimum bid price requirement. During the meeting, it was clarified that should Aditxt’s common stock trade below $1.00 for 30 consecutive days, the company would potentially be eligible for an additional 180 calendar days to regain compliance, provided that all other initial listing standards for The Nasdaq Capital Market are met. The company also disclosed its continued monitoring by a Nasdaq Panel Monitor until December 29, 2024.

In the spirit of transparency, a transcript of the stakeholder update has been furnished and can be found as Exhibit 99.1 in the Current Report on Form 8-K submitted by Aditxt to the Securities and Exchange Commission. It is important to note that the information shared during this session, while being made available, does not constitute a formal filing under the Securities Exchange Act of 1934 and is not to be regarded as incorporated by reference into any registration statement or document filed pursuant to the Securities Act of 1933 unless explicitly referenced.

The company also issued a cautionary note on forward-looking statements contained in the filing, highlighting risk factors such as potential delays in pending transactions, failure to meet closing conditions, and uncertainties associated with financial accounting standards.

Further, Aditxt provided insight into its strategies to address financing needs for current and potential acquisitions without significant dilution, focusing on options like debt financing to support its growth objectives. The company is actively navigating opportunities to fund strategic acquisitions such as Evofem and Appili while emphasizing its commitment to minimizing shareholder dilution.

With Aditxt eyeing a transition towards a more stable and fundamental-driven company, the focus remains on advancing innovations, securing necessary capital, and fostering transparent communication with stakeholders. While challenges persist, the company stands prepared to tackle obstacles and pursue growth initiatives, maintaining a strong mission towards impactful advancements in the biotechnology sector.

Investors and stakeholders are encouraged to engage with Aditxt, submit inquiries, and stay informed about the company’s ongoing activities as it continues its journey of growth and exploration in the healthcare and biotech landscape.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aditxt’s 8K filing here.

About Aditxt

Aditxt, Inc, a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.